ProCE Banner Activity


Improving Provider Awareness About Healthcare Equity: Improving All Patients’ Access to Care in Ovarian Cancer

Text Module

Read insights from Shannon N. Westin, MD, MPH, on health disparities, risk factors, new and emerging treatments, and acknowledging patient preferences to improve outcomes for all patients with ovarian cancer.

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: April 25, 2023

Expiration: April 24, 2024



Shannon N. Westin

Shannon N. Westin, MD, MPH

Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC, in partnership with Smart Patients

ProCE Banner


This activity is supported by educational grants from Eisai, GSK, Karyopharm Therapeutics Inc., Merck Sharp & Dohme, LLC, Seagen and Genmab.



Karyopharm Therapeutics Inc.

Merck Sharp & Dohme, LLC

Seagen and Genmab


Smart Patients

ProCE Banner

Target Audience

This educational program is intended for oncologists, oncology nurses, oncology pharmacists, and other healthcare professionals who care for patients with gynecologic malignancies, as well as patients with gynecologic cancers and their caregivers.

Program Learning Goal

The goal of this activity is to educate oncologists, oncology nurses, pharmacists, and other healthcare professionals, as well as patients/caregivers, about recent developments in the care of gynecologic malignancies and to raise awareness of disparities in care to optimize and individualize the treatment experience for every patient.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Shannon N. Westin, MD, MPH

Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Shannon N. Westin, MD, MPH: consultant/advisor/speaker: AstraZeneca, Caris, Clovis, Eisai, EQRX, Genentech/Roche, GlaxoSmithKline, ImmunoGen, Lilly, Merck, Mereo, Mersana, NGM Bio, Nuvectis, SeaGen, Verastem, Vincerx, Zentalis; researcher: AstraZeneca, AvengeBio, Bayer, Bio-Path, Clovis, Genentech/roche, GlaxoSmithKline, Mereo, Novartis, Zentalis.

The planners and content peer reviewers from Clinical Care Options, LLC and Smart Patients do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 25, 2023, through April 24, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 
CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Nursing Continuing Professional Development 
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-117-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.